Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 03, 2021 16:04 ET | Source: The Rosen Law Firm PA

ROSEN, A LEADING LAW FIRM, Encourages Orphazyme A/S Investors With Losses Over $100K to Secure Counsel Before Important September 7 Deadline in Securities Class Action – ORPH

NEW YORK, Aug. 03, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Orphazyme A/S (NASDAQ: ORPH): (1) pursuant and/or...
June 10, 2021 02:00 ET | Source: Biotalys

Biotalys Nominates Catherine Moukheibir to its Board of Directors

Ghent, BELGIUM, June 10, 2021 (GLOBE NEWSWIRE) -- Biotalys Nominates Catherine Moukheibir to its Board of Directors Highly respected finance and life sciences professional to chair company’s Audit...
July 21, 2019 06:03 ET | Source: ORPHAZYME A/S

Orphazyme to prepare for filing of arimoclomol in US for Niemann-Pick disease Type C (NPC)

Orphazyme A/SCompany announcement No. 18/2019Company Registration No. 32266355 ...
July 18, 2019 01:00 ET | Source: ORPHAZYME A/S

Orphazyme completes enrollment in phase 3 trial evaluating arimoclomol in Amyotrophic Lateral Sclerosis

Orphazyme A/SCompany announcement No. 17/2019 ...
June 07, 2019 00:56 ET | Source: ORPHAZYME A/S

Orphazyme to prepare for filing of arimoclomol in Europe for Niemann-Pick disease Type C (NPC)

Orphazyme A/SCompany announcement No....
August 10, 2018 12:19 ET | Source: ORPHAZYME A/S

Orphazyme announces enrollment of first patient in Phase III clinical trial of arimoclomol for ALS

Orphazyme A/SCompany announcement No....
December 15, 2017 09:20 ET | Source: ORPHAZYME A/S

Orphazyme assumes sponsorship of Phase II/III sIBM trial

Investor newsNo. 01/2017 Orphazyme assumes sponsorship of Phase II/III sIBM trial On December 14, 2017, Orphazyme A/S, University of Kansas Medical Center, and UCL announced that Orphazyme...